About Biognosys
Biognosys is a company based in Schlieren (Switzerland) founded in 2008 was acquired by Bruker in January 2023. Biognosys has raised $9.13 million across 9 funding rounds from investors including Zurcher Kantonalbank, Bruker and European Union. Biognosys offers products and services including TrueDiscovery, Spectronaut, and NULISAseq. Biognosys operates in a competitive market with competitors including Somalogic, Cyrus Biotechnology, Vividion Therapeutics, Nautilus Biotechnology and Amunix, among others.
- Headquarter Schlieren, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biognosys Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.13 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Zurcher Kantonalbank
& 5 more
-
Employee Count
Not available
-
Acquired by
Bruker
(Jan 04, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biognosys
Biognosys offers a comprehensive portfolio of products and services, including TrueDiscovery, Spectronaut, and NULISAseq.
Service for plasma and tissue biomarker identification
Software for DIA proteomics data processing
Multiplex assays for inflammation and CNS protein analysis
Funding Insights of Biognosys
Biognosys has successfully raised a total of $9.13M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biognosys
Biognosys has secured backing from 6 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Zurcher Kantonalbank, Bruker and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are directed toward ICT and health tech startups.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank.
|
Locked | Locked | Locked |
Investor details for Biognosys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biognosys
Investment portfolio details for Biognosys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biognosys
Detailed financials for Biognosys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biognosys Comparisons
Peer comparison for Biognosys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biognosys
Biognosys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Cyrus Biotechnology, Vividion Therapeutics, Nautilus Biotechnology and Amunix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
Detailed competitors of Biognosys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biognosys
Complete news archive for Biognosys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biognosys
Biognosys was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Biognosys is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Biognosys is a funded company, having raised a total of $9.13M across 9 funding rounds to date.
Biognosys was founded in 2008 in Schlieren, Switzerland, and operates within the proteomics sector. Two platforms have been established: discovery proteomics utilizing Hyper Reaction Monitoring for protein identification and quantification, and targeted proteomics employing Multiple and Parallel Reaction Monitoring for predefined proteins. Products offered include workflow kits, multiplexed assay panels such as Plasma dive, and software tools like Spectronaut. Services are provided based on these technologies for research applications.
Biognosys's top competitors include Somalogic, Vividion Therapeutics and Cyrus Biotechnology.
Biognosys offers TrueDiscovery, Spectronaut, and NULISAseq.
Biognosys has 6 investors. Key investors include Zurcher Kantonalbank, Bruker, European Union, Redalpine, and Hellmut Kirchner.